LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ --...
Hence then, the article about novel agent ianalumab added to standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia )
Also on site :
- US cable outlines new ‘construct’ to control Strait of Hormuz – media
- Why are Western feminists silent on the war on Iranian women?
- ’80s Thrash Metal Frontman, Who Survived Rare Cancer, Announces New Project